Management of neuroendocrine tumors of unknown origin
- PMID: 22157557
- DOI: 10.6004/jnccn.2011.0118
Management of neuroendocrine tumors of unknown origin
Abstract
Neuroendocrine tumors (NETs) of unknown origin account for more than 10% of all NETs. Most of these tumors are poorly differentiated and, thus, very aggressive. Establishing the location of the primary tumor can be challenging. Workup of these NETs of unknown origin includes a thorough family history, immunohistochemistry, imaging, and OctreoScan. If the location of the primary malignancy is not determined, treatment is often initiated based on the grade and level of differentiation of the tumor, with well- and moderately differentiated tumors treated as carcinoid tumors, whereas poorly differentiated tumors are treated similarly to small cell tumors. Therapy is chosen based on symptoms and with the goal of debulking tumor when feasible and safe.
Similar articles
-
Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.Am J Surg Pathol. 2017 Jul;41(7):915-922. doi: 10.1097/PAS.0000000000000876. Am J Surg Pathol. 2017. PMID: 28498280
-
ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Neuroendocrinology. 2012;95(2):157-76. doi: 10.1159/000335597. Epub 2012 Feb 15. Neuroendocrinology. 2012. PMID: 22262022 No abstract available.
-
Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?Tumori. 2011 Sep-Oct;97(5):564-7. doi: 10.1177/030089161109700504. Tumori. 2011. PMID: 22158484
-
Update on the management of neuroendocrine hepatic metastases.J Vasc Interv Radiol. 2006 Aug;17(8):1235-49; quiz 1250. doi: 10.1097/01.RVI.0000232177.57950.71. J Vasc Interv Radiol. 2006. PMID: 16923972 Review.
-
The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.Endocr Pathol. 2013 Dec;24(4):184-90. doi: 10.1007/s12022-013-9264-9. Endocr Pathol. 2013. PMID: 24037217
Cited by
-
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors.Nat Genet. 2013 Dec;45(12):1483-6. doi: 10.1038/ng.2821. Epub 2013 Nov 3. Nat Genet. 2013. PMID: 24185511 Free PMC article.
-
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.Front Oncol. 2022 Feb 4;12:780716. doi: 10.3389/fonc.2022.780716. eCollection 2022. Front Oncol. 2022. PMID: 35186729 Free PMC article. Review.
-
Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives.Cancers (Basel). 2024 May 27;16(11):2025. doi: 10.3390/cancers16112025. Cancers (Basel). 2024. PMID: 38893145 Free PMC article. Review.
-
Rare Bone Metastasis of Neuroendocrine Tumors of Unknown Origin: A Case Report and Literature Review.Orthop Surg. 2022 Oct;14(10):2766-2775. doi: 10.1111/os.13384. Epub 2022 Jul 20. Orthop Surg. 2022. PMID: 35856167 Free PMC article. Review.
-
Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors.Nucl Med Mol Imaging. 2021 Feb;55(1):31-37. doi: 10.1007/s13139-020-00677-0. Epub 2021 Jan 7. Nucl Med Mol Imaging. 2021. PMID: 33643487 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources